TARA

Company Overview — What Does Protara Therapeutics, Inc. Do?

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York. Protara Therapeutics, Inc. (TARA) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Jesse Shefferman and employs approximately 30 people, headquartered in NEW YORK, New York. With a market capitalization of $273M, TARA is one of the notable companies in the Healthcare sector.

Protara Therapeutics, Inc. (TARA) Stock Rating — Reduce (April 2026)

As of April 2026, Protara Therapeutics, Inc. receives a Reduce rating with a composite score of 36.5/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.TARA ranks #3,678 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Protara Therapeutics, Inc. ranks #604 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

TARA Stock Price and 52-Week Range

Protara Therapeutics, Inc. (TARA) currently trades at $5.05. The stock lost $0.26 (5.0%) in the most recent trading session. The 52-week high for TARA is $7.82, which means the stock is currently trading -35.5% from its annual peak. The 52-week low is $2.77, putting the stock 82.2% above its annual trough. Recent trading volume was 687K shares, suggesting relatively thin trading activity.

Is TARA Overvalued or Undervalued? — Valuation Analysis

Protara Therapeutics, Inc. (TARA) carries a value factor score of 18/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 1.42x, versus the sector average of 2.75x.

At current multiples, Protara Therapeutics, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Protara Therapeutics, Inc. Profitability — ROE, Margins, and Quality Score

Protara Therapeutics, Inc. (TARA) earns a quality factor score of 26/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -26.1%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -24.5% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

TARA Debt, Balance Sheet, and Financial Health

Protara Therapeutics, Inc. has a debt-to-equity ratio of 7.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 14.58x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $13M.

TARA has a beta of 1.00, meaning it is roughly in line with the broader market in terms of price volatility. The stability factor score for Protara Therapeutics, Inc. is 38/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Protara Therapeutics, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Protara Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.34. Net income for the quarter was $-51M. Operating income came in at $-58M.

In FY 2025, Protara Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.34. Net income for the quarter was $-57M. Operating income came in at $-65M.

In Q3 2025, Protara Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.31. Net income for the quarter was $-13M. Operating income came in at $-15M.

In Q2 2025, Protara Therapeutics, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.35. Net income for the quarter was $-15M. Operating income came in at $-17M.

Over the past 8 quarters, Protara Therapeutics, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing TARA stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

TARA Dividend Yield and Income Analysis

Protara Therapeutics, Inc. (TARA) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

TARA Momentum and Technical Analysis Profile

Protara Therapeutics, Inc. (TARA) has a momentum factor score of 55/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 61/100 reflects moderate short selling activity.

TARA vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Protara Therapeutics, Inc. (TARA) ranks #604 out of 838 stocks based on the Blank Capital composite score. This places TARA in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing TARA against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full TARA vs S&P 500 (SPY) comparison to assess how Protara Therapeutics, Inc. stacks up against the broader market across all factor dimensions.

TARA Next Earnings Date

No upcoming earnings date has been announced for Protara Therapeutics, Inc. (TARA) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy TARA? — Investment Thesis Summary

The quantitative profile for Protara Therapeutics, Inc. suggests caution. The quality score of 26/100 flags below-average profitability. The value score of 18/100 indicates premium valuation. High volatility (stability score 38/100) increases portfolio risk.

In summary, Protara Therapeutics, Inc. (TARA) earns a Reduce rating with a composite score of 36.5/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on TARA stock.

Related Resources for TARA Investors

Explore more research and tools: TARA vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare TARA head-to-head with peers: TARA vs AZN, TARA vs SLGL, TARA vs VMD.